The Albany International Airport has completed the first phase of its Concourse A Rehabilitation Project. Phase one included ...

Lilly’s orforglipron cut body weight as expected in the Phase III ATTAIN-1 trial, but to a lesser extent than rival Novo ...

Quantum Biopharma Ltd. (NASDAQ:QNTM) announced on Tuesday that its subsidiary Huge Biopharma Australia has received the ...

It looks likely we'll see oral GLP-1 drugs on the market by next year, with pharmaceutical company Eli Lilly reporting ...

VALORANT’s Esports Product Manager has revealed a list of tournaments which will offer direct qualification to Project ...

Ucore Rare Metals Inc. (OTCMKTS:UURAF) is one of the best rare earth stocks to buy now. On July 14, the company confirmed all ...

Hemispherian's GLIX1 gains FDA approval for glioblastoma trials, promising a novel therapy targeting DNA repair in tumor ...

Phase 1 results demonstrate that SUL-238, a first-in-class, orally administered, mitochondria-directed drug candidate, is ...

A new leak has revealed the character banner lineup for Genshin Impact 6.0, including characters who will rerun alongside the ...

Led by a team of African researchers, first doses of the novel T cell-inducing GRAdHIVNE1 vaccine candidate have been given.

The Telangana Council of Higher Education (TGCHE) has officially commenced the TS/TG LAWCET 2025 counselling registration ...

Luye Pharma Group today announced that the first subject has been enrolled in a Phase 1 clinical trial in China for its LY03021, which was filed through China's Class 1 pathway for innovative drugs.